Education
About Us
Working with TipRanks
Follow Us
Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
Top Page
Bioline RX Ltd Sponsored ADR
(NASDAQ:BLRX)
48Neutral
Positive Factors
Financial Performance
The company is on sounder financial footing following cessation of U.S. commercial operations, which resulted in an approximately 70% reduction in operating expenses.
Market Share
APHEXDA continues expanding market share, achieving 10% market share of total CXCR4 inhibitor usage in the U.S.
Negative Factors
Clinical Trials
Full enrollment in the Phase IIb trial of motixafortide in pancreatic ductal adenocarcinoma is not expected until 2027, and pancreatic cancer is a particularly intractable disease.
Stock Valuation
The company is fairly valued and is anticipated to trade near current levels until additional data is reported and/or pipeline assets are in licensed.
Bioline RX Ltd Sponsored ADR (BLRX) vs. S&P 500 (SPY)
Market Cap
$11.40M
Dividend YieldN/A
Average Volume (3M)42.62K
Price to Earnings (P/E)―
Beta (1Y)1.71
Revenue GrowthN/A
EPS Growth68.50%
CountryUS
Employees79
SectorHealthcare
Sector Strength65
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.72
Shares Outstanding3,721,003
10 Day Avg. Volume20,775
30 Day Avg. Volume42,621
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.65
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$26.00Price Target Upside790.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bioline RX Ltd Sponsored ADR Business Overview & Revenue Model
Company DescriptionBioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
How the Company Makes MoneyBioline RX Ltd generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model includes potential income from product sales, licensing agreements, and strategic partnerships with larger pharmaceutical firms. These collaborations often involve upfront payments, milestone payments, and royalties on sales, contributing to the company's earnings. Bioline RX's financial strategy also relies on securing funding through public and private investments to support ongoing research, clinical trials, and eventual product launches.
Bioline RX Ltd Sponsored ADR Financial Statement Overview
Summary
BLRX demonstrates growth in revenue but continues to face profitability challenges and relies heavily on borrowing, typical for a biotechnology firm in developmental stages. The current financial trajectory suggests a need for careful management of resources to achieve sustainable operations.Income Statement
BLRX showed a significant increase in revenue in the TTM (Trailing-Twelve-Months), growing from a low base. However, the company remains unprofitable with negative EBIT and net income margins, indicating ongoing operational challenges in achieving profitability.45
Neutral
Balance Sheet
The balance sheet reveals a high debt-to-equity ratio, suggesting leveraged operations, yet a reasonable equity ratio indicates some level of asset backing. The company's equity has decreased over recent periods, potentially impacting its financial stability.50
Neutral
Cash Flow
Free cash flow remains negative, reflecting cash burn, typical in biotechnology for research and development. This is offset by positive financing cash flows, indicating reliance on external funding. The operating cash flow to net income ratio shows divergence, highlighting cash flow challenges.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 21.99M | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 15.13M | 1.11M | -654.00K | -702.00K | -934.00K | -940.00K | EBIT |
| -27.84M | -49.69M | -29.16M | -24.78M | -22.93M | -28.11M | EBITDA |
| -12.36M | -57.06M | -28.50M | -25.35M | -21.99M | -27.17M | Net Income Common Stockholders |
| -19.92M | -60.61M | -18.87M | -28.14M | -30.93M | -26.81M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 25.97M | 42.99M | 51.08M | 57.13M | 22.59M | 27.49M | Total Assets |
| 29.34M | 63.92M | 76.38M | 81.39M | 47.29M | 53.57M | Total Debt |
| 109.56K | 11.59M | 12.32M | 4.65M | 7.68M | 10.46M | Net Debt |
| -8.58M | 7.34M | 1.74M | -8.34M | -9.15M | 5.16M | Total Liabilities |
| 6.81M | 50.70M | 25.54M | 13.30M | 25.26M | 20.19M | Stockholders Equity |
| 22.53M | 13.22M | 50.84M | 68.09M | 22.03M | 33.38M |
| Cash Flow | Free Cash Flow | ||||
| -30.35M | -22.91M | -26.56M | -23.67M | -23.21M | -22.74M | Operating Cash Flow |
| -30.27M | -22.61M | -26.24M | -23.57M | -23.21M | -22.67M | Investing Cash Flow |
| -2.18M | 1.44M | 4.01M | -38.22M | 16.67M | 5.26M | Financing Cash Flow |
| 33.51M | 15.06M | 20.44M | 57.75M | 17.87M | 19.19M |
Bioline RX Ltd Sponsored ADR Technical Analysis
Negative
2.92
Price Trends
3.51
Negative
7.33
Negative
16.07
Negative
Market Momentum
-0.19
Negative
34.79
Neutral
6.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLRX, the sentiment is Negative. The current price of 2.92 is below the 20-day moving average (MA) of 3.21, below the 50-day MA of 3.51, and below the 200-day MA of 16.07, indicating a bearish trend. The MACD of -0.19 indicates Negative momentum. The RSI at 34.79 is Neutral, neither overbought nor oversold. The STOCH value of 6.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLRX.
Bioline RX Ltd Sponsored ADR Risk Analysis
Bioline RX Ltd Sponsored ADR disclosed 43 risk factors in its most recent earnings report. Bioline RX Ltd Sponsored ADR reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioline RX Ltd Sponsored ADR Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
48 Neutral | $11.40M | ― | -184.09% | ― | ― | 68.50% | |
45 Neutral | $10.85M | 1.04 | -85.36% | ― | -70.05% | ― | |
42 Neutral | $11.55M | ― | -490.03% | ― | ― | 98.97% | |
40 Underperform | $10.71M | ― | -8.16% | ― | 35.25% | 81.05% | |
38 Underperform | $11.20M | ― | -66.65% | ― | 157.63% | 40.52% | |
33 Underperform | $13.75M | ― | -90.91% | ― | -31.04% | 74.62% |
* Healthcare Sector Average
Performance Comparison
BLRX
Bioline RX Ltd Sponsored ADR
2.92
-30.20
-91.18%
TXMD
TherapeuticsMD
0.98
-1.24
-55.86%
ABVC
ABVC BioPharma, Inc.
1.32
0.03
2.33%
APRE
Aprea Therapeutics
1.92
-4.75
-71.21%
ADXN
Addex Therapeutics
7.10
-8.30
-53.90%
RNAZ
TransCode Therapeutics
0.54
-20.91
-97.48%
Bioline RX Ltd Sponsored ADR Earnings Call Summary
Earnings Call Date: Mar 31, 2025 | % Change Since: -4.26% | Next Earnings Date: May 21, 2025
Earnings Call Sentiment Positive
The earnings call highlights BioLineRx's transformational licensing agreement and significant revenue growth, indicating a positive outlook with a strong financial position and promising clinical developments. However, the shutdown of U.S. operations and challenges in PDAC development highlight ongoing strategic adjustments.Highlights
Transformational Licensing Agreement with Ayrmid Pharma
BioLineRx executed an exclusive license agreement with Ayrmid Pharma Ltd. for motixafortide, generating $10 million in upfront payments and eligibility for $87 million in potential milestones, along with 18% to 23% sales royalties.
Significant Revenue Growth
Total revenues for 2024 were $28.9 million, a 502.1% increase from $4.8 million in 2023, driven by upfront payments and milestones from licensing agreements.
Operational Streamlining and Cost Reduction
BioLineRx reduced operating cash burn by approximately 70%, from over $40 million annually to about $12 million, following the shutdown of U.S. operations and headcount reduction in Israel.
Strong Financial Position
BioLineRx ended 2024 with $29 million in pro forma cash and a cash runway projected to fund operations through the second half of 2026.
Promising Clinical Developments in Sickle Cell Disease
Positive initial results from motixafortide trials in sickle cell disease, showing the potential to mobilize enough stem cells for gene therapies in fewer cycles.
Lowlights
Shutdown of U.S. Operations
BioLineRx shut down its U.S. operations as part of a strategic shift, impacting its commercial team and potentially reducing direct market engagement.
Challenges in PDAC Development
Development of motixafortide in pancreatic ductal carcinoma (PDAC) remains challenging, with full enrollment in the Phase 2b study not expected until 2027.
High Sales and Marketing Expenses
Sales and marketing expenses for 2024 were $23.6 million, only a slight decrease of 6.7% from 2023, despite the shutdown of U.S. commercial operations.
Company Guidance
During the BioLineRx Fourth Quarter and Full Year 2024 Financial Results Conference Call, CEO Phil Serlin highlighted key metrics reflecting the company's strategic shift and financial performance. BioLineRx executed an exclusive license agreement with Ayrmid Pharma Ltd. for motixafortide, generating $10 million in upfront payments and making the company eligible for $87 million in potential milestones and sales royalties ranging from 18% to 23%. The company reported total revenues of $28.9 million for 2024, a 502.1% increase from 2023. The shutdown of U.S. operations and headcount reduction in Israel reduced annual operating cash burn by 70%, from over $40 million to approximately $12 million. Additionally, BioLineRx ended the year with pro forma cash of $29 million and a cash runway projected to fund operations through the second half of 2026. The company is focused on expanding its pipeline by evaluating early clinical stage and late pre-clinical stage therapeutic assets in oncology and rare diseases, leveraging its drug development expertise.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.